Skip to main content
SpringerLink
Log in

Optimizing the Use of Anticoagulants (Heparins and Oral Anticoagulants) in the Elderly

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

As longevity constantly increases, the number of elderly patients (75 years and older) who require anticoagulation likewise rises steadily. Managing elderly patients receiving anticoagulants is challenging because those patients are at high risk of both thrombosis and bleeding. Moreover, older patients are commonly frail: they have substantial chronic co-morbid conditions including renal impairment and frequent acute illnesses and are often polymedicated. There remains a clear need to optimize the use of anticoagulant drugs in these patients, especially at full anticoagulant dose. In the last decade, efforts have been made to better understand the inter-individual variability in the response of elderly patients to traditional anticoagulants including heparin derivatives (unfractionated heparin, low molecular weight heparins and fondaparinux) and vitamin K antagonists. Moreover, their safety profile has been evaluated in different settings in the elderly, assisting in minimizing risks related to their use. Emergence of new oral anticoagulants (dabigatran, rivaroxaban, apixaban), which appear to be much more convenient, is promising. Even though some elderly patients were included in pivotal clinical trials evaluating these new anticoagulants, the safety of these drugs remains uncertain in real life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Spencer FA, Gore JM, Lessard D, et al. Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost. 2008;100(5):780–8.

    PubMed  CAS  Google Scholar 

  2. Stein PD, Hull RD, Kayali F, et al. Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med. 2004;164(20):2260–5.

    Article  PubMed  Google Scholar 

  3. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949–53.

    Article  PubMed  Google Scholar 

  4. Avezum A, Makdisse M, Spencer F, GRACE Investigators, et al. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2005;149(1):67–73.

    Article  PubMed  Google Scholar 

  5. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. Br Med J. 2002;325(7368):828–31.

    Article  Google Scholar 

  6. Garg AX, Papaioannou A, Ferko N, et al. Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int. 2004;65(2):649–53.

    Article  PubMed  Google Scholar 

  7. Krähenbühl-Melcher A, Schlienger R, Lampert M, et al. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30(5):379–407.

    Article  PubMed  Google Scholar 

  8. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S–88S.

    Article  PubMed  CAS  Google Scholar 

  9. Swedko PJ, Clark HD, Paramsothy K, et al. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med. 2003;163(3):356–60.

    Article  PubMed  CAS  Google Scholar 

  10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.

    Article  PubMed  CAS  Google Scholar 

  11. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–54 (Erratum in: Ann Intern Med. 2008;149(7):519).

    Google Scholar 

  12. Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12 (Erratum in: Ann Intern Med. 2011;155(6):408).

    Google Scholar 

  13. Poli D, Antonucci E, Zanazzi M, et al. Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). Thromb Haemost. 2012;107:1100–6.

    Article  PubMed  CAS  Google Scholar 

  14. Stengel B, Metzger M, Froissart M, et al. Epidemiology and prognostic significance of chronic kidney disease in the elderly—the Three-City prospective cohort study. Nephrol Dial Transplant. 2011;26:3286–95.

    Article  PubMed  Google Scholar 

  15. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.

    Article  PubMed  CAS  Google Scholar 

  16. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

    Article  PubMed  CAS  Google Scholar 

  17. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

    Article  PubMed  CAS  Google Scholar 

  18. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17.

    Article  PubMed  CAS  Google Scholar 

  19. Gouin-Thibault I, Pautas E, Mahé I, et al. Is Modification of Diet in Renal Disease formula similar to Cockcroft–Gault formula to assess renal function in elderly hospitalized patients treated with low-molecular-weight heparin? J Gerontol A Biol Sci Med Sci. 2007;62(11):1300–5.

    Article  PubMed  Google Scholar 

  20. Mismetti P, Samama CM, Rosencher N, PROPICE Study Group, et al. Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study. Thromb Haemost. 2012;107:1151–60.

    Article  PubMed  CAS  Google Scholar 

  21. Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e24S–43S (Erratum in: Chest. 2012;141(5):1369).

  22. Steg PG, James SK, Atar D, et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–619.

    Article  PubMed  CAS  Google Scholar 

  23. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: LMWH and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144(9):673–84.

    Article  PubMed  CAS  Google Scholar 

  24. Samama MM. Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment. Drugs Aging. 2011;28(3):177–93.

    Article  PubMed  CAS  Google Scholar 

  25. Mismetti P, Laporte-Simitsidis S, Navarro C, et al. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost. 1998;79(6):1162–5.

    PubMed  CAS  Google Scholar 

  26. Siguret V, Pautas E, Février M, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost. 2000;84(5):800–4.

    PubMed  CAS  Google Scholar 

  27. Pautas E, Gouin I, Bellot O, et al. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf. 2002;25(10):725–33.

    Article  PubMed  CAS  Google Scholar 

  28. Chow SL, Zammit K, West K, et al. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol. 2003;43(6):586–90.

    PubMed  CAS  Google Scholar 

  29. Tincani E, Mannucci C, Casolari B, et al. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica. 2006;91(7):976–9.

    PubMed  CAS  Google Scholar 

  30. Mahé I, Aghassarian M, Drouet L, et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function. Thromb Haemost. 2007;97(4):581–6.

    PubMed  Google Scholar 

  31. Berges A, Laporte S, Epinat M, et al. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. Br J Clin Pharmacol. 2007;64(4):428–38.

    Article  PubMed  CAS  Google Scholar 

  32. Schmid P, Brodmann D, Odermatt Y, et al. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. J Thromb Haemost. 2009;7(10):1629–32.

    Article  PubMed  CAS  Google Scholar 

  33. Siguret V, Gouin-Thibault I, Pautas E, et al. No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy. J Thromb Haemost. 2011;9(10):1966–72.

    Article  PubMed  CAS  Google Scholar 

  34. Dufour B, Toussaint-Hacquard M, Kearney-Schwartz A, et al. Glomerular filtration rate estimated by Cockcroft–Gault formula better predicts anti-Xa levels than modification of the diet in renal disease equation in older patients with prophylactic enoxaparin. J Nutr Health Aging. 2012;16(7):647–52.

    Article  PubMed  CAS  Google Scholar 

  35. Nagler M, Haslauer M, Wuillemin WA. Fondaparinux—data on efficacy and safety in special situations. Thromb Res. 2012;129(4):407–17.

    Article  PubMed  CAS  Google Scholar 

  36. Thorevska N, Amoateng-Adjepong Y, Sabahi R, et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest. 2004;125(3):856–63.

    Article  PubMed  CAS  Google Scholar 

  37. López-Jiménez L, Montero M, González-Fajardo JA, Arcelus JI, Suárez C, Lobo JL, Lobo M, RIETE Investigators. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica. 2006;91(8):1046–51.

    PubMed  Google Scholar 

  38. Vasco B, Villalba JC, Lopez-Jimenez L, RIETE Investigators, et al. Venous thromboembolism in nonagenarians. Findings from the RIETE Registry. Thromb Haemost. 2009;101(6):1112–8.

    PubMed  CAS  Google Scholar 

  39. Levin A, Ben-Artzi M, Beckerman P, Haber G, Varon D, Ben-Yehuda A, Muszkat M. Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium: a prospective, open-label, observational study. Drugs Aging. 2009;26(1):77–85.

    Article  PubMed  CAS  Google Scholar 

  40. Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Antman EM, TIMI 11A Investigators. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2002;143(5):753–9.

    Article  PubMed  CAS  Google Scholar 

  41. Collet JP, Montalescot G, Fine E, et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol. 2003;41(1):8–14.

    Article  PubMed  CAS  Google Scholar 

  42. Montalescot G, Collet JP, Tanguy ML, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation. 2004;110(4):392–8.

    Article  PubMed  CAS  Google Scholar 

  43. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol. 1997;29(7):1474–82.

    Article  Google Scholar 

  44. Boneu B, de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Hemost. 2001;27(5):519–22.

    Article  PubMed  CAS  Google Scholar 

  45. Harenberg J. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes. J Thromb Haemost. 2004;2(4):547–50.

    Article  PubMed  CAS  Google Scholar 

  46. Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost. 2004;2(4):551–4.

    Article  PubMed  CAS  Google Scholar 

  47. Gouin-Thibault I, Siguret V, Pautas E. A need for evidence-based clinical practice guidelines for the use of heparins in the elderly. Clin Interv Aging. 2010;26:119–21.

    Article  Google Scholar 

  48. Campbell N, Hull R, Brant R, et al. Aging and heparin-related bleeding. Arch Intern Med. 1996;156(8):857–60.

    Article  PubMed  CAS  Google Scholar 

  49. Alexander KP, Newby LK, Armstrong PW, et al. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007;115(19):2570–89.

    Article  PubMed  Google Scholar 

  50. Alexander KP, Newby LK, Cannon CP, et al. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007;115(19):2549–69.

    Article  PubMed  Google Scholar 

  51. Lopes RD, Alexander KP, Marcucci G, et al. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. Eur Heart J. 2008;29(15):1827–33.

    Article  PubMed  CAS  Google Scholar 

  52. Puymirat E, Aïssaoui N, Collet JP, et al. Comparison of bleeding complications and one-year survival of low molecular weight heparin versus unfractioned heparin for acute myocardial infarction in elderly patients. The FAST-MI registry. Int J Cardiol. 2011;154(3):373–6.

    PubMed  Google Scholar 

  53. Leizorovicz A, Siguret V, Mottier D, et al. Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in Renal Insufficiency Study (IRIS). Thromb Res. 2011;128(1):27–34.

    Article  PubMed  CAS  Google Scholar 

  54. Guidelines AGS. The use of oral anticoagulants (warfarin) in older people. J Am Geriatr Soc. 2002;50(8):1439–45.

    Article  Google Scholar 

  55. Ogilvie JM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–45.

    Article  PubMed  CAS  Google Scholar 

  56. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84(3):326–31.

    Article  PubMed  CAS  Google Scholar 

  57. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753–64.

    Article  Google Scholar 

  58. Redwood M, Taylor C, Bain BJ, et al. The association of age with dosage requirement for warfarin. Age Ageing. 1991;20(3):217–20.

    Article  PubMed  CAS  Google Scholar 

  59. Penning-van Beest FJ, van Meegen E, Rosendaal FR, et al. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost. 2001;86(2):569–74.

    PubMed  CAS  Google Scholar 

  60. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S–84S.

    Article  PubMed  CAS  Google Scholar 

  61. Siguret V, Esquirol C, Debray M, et al. Excess antivitamin K in elderly hospitalised patients aged over 70. A one-year prospective survey. Presse Med. 2003;32(21):972–7.

    PubMed  CAS  Google Scholar 

  62. Pautas E, Peyron I, Bouhadiba S, et al. Reversal of overanticoagulation in very elderly hospitalized patients with an INR above 5.0: 24-hour INR response after vitamin K administration. Am J Med. 2011;124(6):527–33.

    Article  PubMed  CAS  Google Scholar 

  63. Froom P, Miron E, Barak M. Oral anticoagulants in the elderly. Br J Haematol. 2003;120(3):526–8.

    Article  PubMed  Google Scholar 

  64. Comets E, Diquet B, Legrain S, et al. Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians. Clin Pharmacol Ther. 2012;91(5):777–86.

    Article  PubMed  CAS  Google Scholar 

  65. Pautas E, Moreau C, Gouin-Thibault I, et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther. 2010;87(1):57–64.

    Article  PubMed  CAS  Google Scholar 

  66. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348(9025):423–8.

    Article  PubMed  CAS  Google Scholar 

  67. Palareti G, Hirsh J, Legnani C, et al. Oral anticoagulation treatment in the elderly: a nested, prospective, case–control study. Arch Intern Med. 2000;160(4):470–8.

    Article  PubMed  CAS  Google Scholar 

  68. Poli D, Antonucci E, Testa S, et al. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation. 2011;124:824–9.

    Article  PubMed  CAS  Google Scholar 

  69. Gedge J, Orme S, Hampton KK, et al. A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing. 2000;29(1):31–4.

    Article  PubMed  CAS  Google Scholar 

  70. Siguret V, Gouin I, Debray M, et al. Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen. Am J Med. 2005;118(2):137–42.

    Article  PubMed  CAS  Google Scholar 

  71. Moreau C, Pautas E, Gouin-Thibault I, et al. Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes. J Thromb Haemost. 2011;9(4):711–8.

    Article  PubMed  CAS  Google Scholar 

  72. Gouin-Thibault I, Levy C, Pautas E, et al. Improving anticoagulation control in hospitalized elderly patients on warfarin. J Am Geriatr Soc. 2010;58(2):242–7.

    Article  PubMed  Google Scholar 

  73. Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159(7):677–85.

    Article  PubMed  CAS  Google Scholar 

  74. Witt DM, Delate T, Clark NP, Warped Consortium, et al. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost. 2010;8:744–9.

    Article  PubMed  CAS  Google Scholar 

  75. Rose AJ, Berlowitz DR, Miller DR, et al. INR targets and site-level anticoagulation control: results from the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost. 2012;10(4):590–5.

    Article  PubMed  CAS  Google Scholar 

  76. Waterman AD, Milligan PE, Bayer L, et al. Effect of warfarin nonadherence on control of the International Normalized Ratio. Am J Health Syst Pharm. 2004;61(12):1258–64.

    PubMed  Google Scholar 

  77. Khan TI, Kamali F, Kesteven P, et al. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol. 2004;126(4):557–64.

    Article  PubMed  Google Scholar 

  78. Kagansky N, Knobler H, Rimon E, et al. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med. 2004;164(18):2044–50.

    Article  PubMed  Google Scholar 

  79. Beasley BN, Unger EF, Temple R. Anticoagulant options—why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364(19):1788–90.

    Article  PubMed  CAS  Google Scholar 

  80. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RELY trial. N Engl J Med. 2010;363(19):1875–6.

    Article  PubMed  CAS  Google Scholar 

  81. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RELY) trial. Circulation. 2011;123(21):2363–72.

    Article  PubMed  CAS  Google Scholar 

  82. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of Aged study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503.

    Article  PubMed  CAS  Google Scholar 

  83. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial haemorrhages. Am J Med. 2007;120(8):700–5.

    Article  PubMed  Google Scholar 

  84. Jacobs JM, Stessman J. New anticoagulant drugs among elderly patients. Is caution necessary? Arch Intern Med. 2011;171(14):1287–8.

    Article  PubMed  Google Scholar 

  85. Dahl OE. Dabigatran etexilate: an oral direct thrombin inhibitor. Therapy. 2008;5:685–95.

    Article  CAS  Google Scholar 

  86. Stangier J, Stähle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in health elderly subjects. Clin Pharmacokinet. 2008;47(1):47–59.

    Article  PubMed  CAS  Google Scholar 

  87. Stangier J, Rathgen K, Stähle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet. 2010;49(4):259–68.

    Article  PubMed  CAS  Google Scholar 

  88. Troconiz IF, Tillmann C, Liesenfeld KH, et al. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacol. 2007;47(3):371–82.

    Article  PubMed  CAS  Google Scholar 

  89. Jiang J, Hu Y, Zhang J, et al. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban—an oral, direct factor Xa inhibitor—in elderly Chinese subjects. Thromb Haemost. 2010;103(1):234–41.

    Article  PubMed  CAS  Google Scholar 

  90. Davis EM, Packard KA, Knezevitch JT, et al. New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome. Pharmacotherapy. 2011;31(10):975–1016.

    Article  PubMed  CAS  Google Scholar 

  91. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetic and pharmacodynamics of rivaroxaban, an oral, direct factor Xa inhibitor, in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008;47(3):203–16.

    Article  PubMed  CAS  Google Scholar 

  92. Jungbauer L, Dobias C, Stöllberger C, et al. The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation. J Thromb Haemost. 2010;8(9):2069–70.

    Article  PubMed  CAS  Google Scholar 

  93. van Ryn J, Stangier J, Haerter S, et al. Dabigatran etexilate, a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–27.

    Article  PubMed  Google Scholar 

  94. Erenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–9.

    Article  Google Scholar 

  95. Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation. Arch Intern Med. 2012;172(8):623–31.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

V. Siguret has participated in expert meetings for Poxel, Bayer and BMS-Pfizer. I. Gouin-Thibault has participated in expert meetings for Bayer, BMS and Boehringer Ingelheim. E. Pautas has participated in training sessions for Bayer and Sanofi. P. Gaussem has no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Université Paris Descartes, Sorbonne Paris Cité, Paris, France

    Virginie Siguret, Isabelle Gouin-Thibault, Pascale Gaussem & Eric Pautas

  2. INSERM UMR-S765, 4 avenue de l’Observatoire, Paris, France

    Virginie Siguret, Isabelle Gouin-Thibault, Pascale Gaussem & Eric Pautas

  3. Service d’Hématologie biologique, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France

    Virginie Siguret & Pascale Gaussem

  4. Service d’Hématologie biologique, Assistance Publique Hôpitaux de Paris, GH Cochin-Hôtel-Dieu, Paris, France

    Isabelle Gouin-Thibault

  5. Unité de gériatrie aiguë, Assistance Publique Hôpitaux de Paris, GH Pitié-Salpêtrière-Charles Foix, Ivry-sur-Seine, France

    Eric Pautas

Authors
  1. Virginie Siguret
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Isabelle Gouin-Thibault
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pascale Gaussem
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eric Pautas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Virginie Siguret.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siguret, V., Gouin-Thibault, I., Gaussem, P. et al. Optimizing the Use of Anticoagulants (Heparins and Oral Anticoagulants) in the Elderly. Drugs Aging 30, 687–699 (2013). https://doi.org/10.1007/s40266-013-0101-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-013-0101-0

Keywords

Search

Navigation